Monday, June 27, 2016
Intralesional PV-10 (Rose Bengal, y'all!!!) positive treatment for in-transit melanoma
I've certainly posted about intralesional therapies (including Rose Bengal/PV-10) before. Here's just one link: ASCO 2016 - New studies on intralesional therapy Treating in-transit melanoma can certainly be a challenge. Now a report on one center's experience:
Intralesional PV-10 for in-transit melanoma-A single-center experience. Lippey, Bousounis, Behrenbruch, et al. J Surg Oncol. 2016 May 30.
Patients with in-transit melanoma metastasis have longer median survival than patients with distant metastatic disease. Furthermore, local disease control is an important endpoint for symptom management. The treatment of unresectable loco-regional recurrence or in-transit disease has been historically managed with a combination of treatments including surgery, radiotherapy, isolated limb infusion or perfusion as well as systemic therapies. Intralesional PV-10 has been used at Peter MacCallum Cancer Centre since 2010, and the current report presents a retrospective analysis of patient outcomes, reporting the response rates, durability of responses, and observed toxicities. Records were analyzed retrieving details of 19 patients treated with PV-10 over a 4-year period from 2010 to 2014. Medical records were reviewed for these patients and data extracted. Nineteen patients with in-transit melanoma were treated with intralesional PV-10 between 2010 and 2014. Disease control (complete or partial response or disease stability) was achieved in 68% of patients with 26% having a complete response. This was achieved with minimal associated toxicity. PV-10 is an effective, durable, well-tolerated treatment tool with an acceptable side effect profile for the management of unresectable in-transit melanoma.
Hopefully, when combined with pembro or other systemic treatments...the complete response rate can be bumped higher!!! Hold onto your tails, ratties! - c